MTMichał Tworek

Michał Tworek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michał Tworek has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Katarzyna Holcman

    Department of Cardiac and Vascular Diseases, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Katarzyna Trojanowicz

    Department of Cardiac and Vascular Diseases, Krakow Specialist Hospital Named After St. John Paul II, ul. Prądnicka 80, 31-202 Krakow, Poland

    1 shared publication
  • Klaudia Bielecka

    Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Klaudia Pacia

    Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Monika Komar

    Department of Cardiac and Vascular Diseases, Institute of Cardiology, St. John Paul II Hospital, Jagiellonian University Medical College, 31-202 Krakow, Poland

    1 shared publication
  • Piotr Podolec

    Department of Cardiac and Vascular Diseases, The St. John Paul II Hospital, Prądnicka 80, 31-202 Kraków, Poland

    1 shared publication

Latest Publications

  • Open Access

    Looking for Fabry, Finding More: LVH Screening Yields Unexpected Gaucher Diagnosis

    by Sylwia Szczepara, Klaudia Pacia, Katarzyna Trojanowicz, Klaudia Bielecka, Michał Tworek, Zuzanna Sachajko, Katarzyna Holcman, Piotr Podolec, Monika Komar

    Objective: Fabry disease (FD) is a rare, X-linked lysosomal storage disorder resulting from deficient α-galactosidase A activity, which can manifest as left ventricular hypertrophy (LVH). We aimed to assess the prevalence of FD in an unselected cohort of patients with unexplained LVH. Methods and results: We screened 202 unrelated adults with LVH using enzymatic assays for α-galactosidase A in dried blood spots. Patients with low activity underwent GLA gene sequencing. Echocardiographic parameters were evaluated according to ESC guidelines. FD was diagnosed in 4 women (2%), each carrying distinct pathogenic GLA mutations. All affected individuals showed normal or borderline enzyme activity. Cardiac, renal, or neurological symptoms were observed variably among patients. Echocardiographic findings revealed slightly lower wall thickness and preserved systolic function in FD patients compared to those without FD. Cascade genetic screening identified 16 additional family members with the same mutations. One patient (0.5%) was incidentally diagnosed with Gaucher disease based on syndromic features and enzymatic testing. Conclusions: FD was identified in 2% of patients with unexplained LVH, who were females. Enzyme-based screening followed by targeted genetic testing is a cost-effective strategy for FD detection. Early diagnosis is essential for prompt treatment and family counselling, underscoring the importance of routine FD screening in patients with LVH of unclear aetiology. Our findings support the use of targeted screening for Fabry disease in patients with LVH and systemic features, and highlight the potential to identify other lysosomal disorders in selected cases.